Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Current Leases (2019 - 2025)

Ocular Therapeutix (OCUL) has 7 years of Current Leases data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Current Leases rose 45.73% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 45.73%, while the annual FY2025 figure was $2.8 million, 45.73% up from the prior year.
  • Current Leases reached $2.8 million in Q4 2025 per OCUL's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Current Leases topped out at $2.8 million in Q4 2025 and bottomed at $1.4 million in Q1 2021.
  • Average Current Leases over 5 years is $1.9 million, with a median of $1.7 million recorded in 2023.
  • Peak YoY movement for Current Leases: decreased 15.18% in 2024, then soared 60.86% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.6 million in 2021, then decreased by 1.54% to $1.6 million in 2022, then fell by 0.81% to $1.6 million in 2023, then rose by 21.88% to $1.9 million in 2024, then soared by 45.73% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $2.8 million in Q4 2025, $2.8 million in Q3 2025, and $2.6 million in Q2 2025.